Metraipolis › archive › dc_170c7575836d

Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy — Europe PMC PMID:40869319

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40869319
DOI
10.3390/ijms26167998
License (as archived)
solo-consultazione
Archived
2026-11-10T12:47:40.965Z
SHA-256 of the archived text
6e41f4546c88e2ed29e4372126e18292b9d0816379d319035121ef232c92131a
Stable URL of this page
https://metraipolis.com/documento/dc_170c7575836d

How to cite

Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy — Europe PMC PMID:40869319 — Europe PMC (en), https://europepmc.org/article/MED/40869319 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_170c7575836d (Metraipolis archive dc_170c7575836d, sha256 6e41f4546c88e2ed29e4372126e18292b9d0816379d319035121ef232c92131a)
BibTeX
@misc{dc170c7575836d,
  title = {Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy — Europe PMC PMID:40869319},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40869319},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_170c7575836d; sha256 6e41f4546c88e2ed29e4372126e18292b9d0816379d319035121ef232c92131a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40869319. Agents can read the archived copy with the MCP tool read_document.